Pepkon
About
Pepkon is a French biotechnology company developing first-in-class peptides to treat refractory and incurable cancers. Leveraging ten years of academic research, Pepkon designs CD47-agonist peptides derived from thrombospondin-1 (TSP-1).
Backed by patents filed in 2025, Pepkon is currently conducting pharmacological and toxicity studies, and will start IND-enabling studies in a few months on its lead candidate.
MEDICINE
Cytology, Cancerology, OncologyPharmaceutical Products / Drugs
THERAPEUTIC AREA
HematologyImmunologyOncologyPediatrics/NeonatologyPharmacology/ToxicologyRare Disease
LIFE SCIENCE
Therapy and physical medicine
Representatives
Project manager
Pepkon
CEO
Pepkon